Zuellig Pharma Specialty Solutions Group
Zuellig Pharma Specialty Solutions Group is recorded as a service provider in 3 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 3 of 3 trials · Latest update first
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia
Sponsor BeOne Medicines AG
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Randomized, Double-Blind Study of Ociperlimab, an Anti-TIGIT Antibody, in Combination With Tislelizumab Compared to Pembrolizumab in Patients With Previously Untreated, PD-L1-Selected, and Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer
Sponsor Beigene Ltd.
- Start (EU)
- Latest update
- Estimated end
A Phase 3 Clinical Trial to Compare Efficacy, Safety, Tolerability and Immunogenicity of RBS-001 to Eylea® in Subjects with Neovascular Age-Related Macular Degeneration
Sponsor Rophibio Inc.
- Start (EU)
- Not reported
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Zuellig Pharma Specialty Solutions Group?
The 2026-10-09 snapshot links Zuellig Pharma Specialty Solutions Group to 3 distinct CTIS trials. Recorded services include Medicinal product management, clinical supply vendor. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Zuellig Pharma Specialty Solutions Group?
The most frequently recorded therapeutic areas are Haematological Malignancies. Recorded phases include Phase 3. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Zuellig Pharma Specialty Solutions Group conducted?
The linked trials record locations in 12 countries, including Poland, Germany, Spain, France, Italy. These are trial locations, not confirmed office locations or countries where Zuellig Pharma Specialty Solutions Group delivered services.
What can this page tell me about Zuellig Pharma Specialty Solutions Group's trial experience?
Browse 3 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Zuellig Pharma Specialty Solutions Group. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Zuellig Pharma Specialty Solutions Group Pte. Ltd.